CY1105545T1 - Θεραπεια στατινης για ενισχυση της διατηρησης νοητικης λειτουργιας - Google Patents

Θεραπεια στατινης για ενισχυση της διατηρησης νοητικης λειτουργιας

Info

Publication number
CY1105545T1
CY1105545T1 CY20061101397T CY061101397T CY1105545T1 CY 1105545 T1 CY1105545 T1 CY 1105545T1 CY 20061101397 T CY20061101397 T CY 20061101397T CY 061101397 T CY061101397 T CY 061101397T CY 1105545 T1 CY1105545 T1 CY 1105545T1
Authority
CY
Cyprus
Prior art keywords
preservation
enhance
statin
statin therapy
mental function
Prior art date
Application number
CY20061101397T
Other languages
Greek (el)
English (en)
Inventor
Sean Lilienfeld
Elane M. Gutterman
Royston John Glasspool
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of CY1105545T1 publication Critical patent/CY1105545T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CY20061101397T 2002-04-02 2006-09-27 Θεραπεια στατινης για ενισχυση της διατηρησης νοητικης λειτουργιας CY1105545T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36928502P 2002-04-02 2002-04-02
PCT/EP2003/003324 WO2003082298A1 (en) 2002-04-02 2003-03-28 Statin therapy for enhancing cognitive maintenance

Publications (1)

Publication Number Publication Date
CY1105545T1 true CY1105545T1 (el) 2010-07-28

Family

ID=28675573

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101397T CY1105545T1 (el) 2002-04-02 2006-09-27 Θεραπεια στατινης για ενισχυση της διατηρησης νοητικης λειτουργιας

Country Status (21)

Country Link
EP (1) EP1492539B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005525391A (cg-RX-API-DMAC7.html)
KR (1) KR100986194B1 (cg-RX-API-DMAC7.html)
CN (1) CN100528164C (cg-RX-API-DMAC7.html)
AT (1) ATE331523T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003226753B2 (cg-RX-API-DMAC7.html)
BR (1) BR0308293A (cg-RX-API-DMAC7.html)
CA (1) CA2480275C (cg-RX-API-DMAC7.html)
CY (1) CY1105545T1 (cg-RX-API-DMAC7.html)
DE (1) DE60306503T2 (cg-RX-API-DMAC7.html)
DK (1) DK1492539T3 (cg-RX-API-DMAC7.html)
EA (1) EA013069B1 (cg-RX-API-DMAC7.html)
ES (1) ES2268393T3 (cg-RX-API-DMAC7.html)
IL (2) IL164317A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04009535A (cg-RX-API-DMAC7.html)
NO (1) NO20044698L (cg-RX-API-DMAC7.html)
NZ (1) NZ536111A (cg-RX-API-DMAC7.html)
PL (1) PL211160B1 (cg-RX-API-DMAC7.html)
PT (1) PT1492539E (cg-RX-API-DMAC7.html)
UA (1) UA79605C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003082298A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
EP1737539A1 (en) * 2004-04-14 2007-01-03 Warner-Lambert Company LLC Therapeutic combination for treatment of alzheimers disease
EP1604686A1 (en) * 2004-06-08 2005-12-14 Axonyx, Inc. Use of phenserine and a HMG CoA reductase inhibitor for delaying Alzheimer's disease progression
GB0607946D0 (en) * 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
AU2007299726A1 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
TWI432195B (zh) 2007-10-03 2014-04-01 Kowa Co 神經細胞死亡抑制劑
US20160303146A1 (en) * 2013-12-13 2016-10-20 David A. TABACZYNSKI Inhibition of isoprenoid biosynthetic pathways to treat neuroinflammatory disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet

Also Published As

Publication number Publication date
PL211160B1 (pl) 2012-04-30
CN100528164C (zh) 2009-08-19
PT1492539E (pt) 2006-11-30
KR100986194B1 (ko) 2010-10-07
DE60306503T2 (de) 2007-06-21
DK1492539T3 (da) 2006-10-30
PL371551A1 (en) 2005-06-27
IL164317A0 (en) 2005-12-18
AU2003226753B2 (en) 2007-06-28
AU2003226753A1 (en) 2003-10-13
NZ536111A (en) 2006-03-31
NO20044698L (no) 2004-10-29
ATE331523T1 (de) 2006-07-15
EA200401295A1 (ru) 2005-02-24
DE60306503D1 (de) 2006-08-10
HK1079688A1 (zh) 2006-04-13
JP2005525391A (ja) 2005-08-25
CN1642555A (zh) 2005-07-20
MXPA04009535A (es) 2005-01-25
EP1492539B1 (en) 2006-06-28
UA79605C2 (en) 2007-07-10
EP1492539A1 (en) 2005-01-05
ES2268393T3 (es) 2007-03-16
BR0308293A (pt) 2004-12-28
KR20040096608A (ko) 2004-11-16
IL164317A (en) 2010-04-29
EA013069B1 (ru) 2010-02-26
CA2480275C (en) 2011-08-16
WO2003082298A1 (en) 2003-10-09
CA2480275A1 (en) 2003-10-09

Similar Documents

Publication Publication Date Title
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
NO20053077L (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
NO20061325L (no) Kombinasjon av legemidler for behandling av neoplasmer
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
DE69400799D1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
CY1115719T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
WO2001054681A8 (en) Composition for treatment of stress
ATE369355T1 (de) Pyrimidinamid derivate und deren verwendung
CY1105000T1 (el) Χρηση της σπινοσαδης ή μιας συνθεσεως περιεχουσης σπινοσαδη
CY1109013T1 (el) Νεα 4,4΄-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικα) παραγωγα και συνθεσεις που τα περιεχουν
RU94026283A (ru) Фармацевтическое соединение
DK0796103T3 (da) Anvendelse af røgelse til behandling af Alzheimer-sygdommen
DE602004031631D1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
RU2007104774A (ru) Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
ATE404192T1 (de) Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
ATE333897T1 (de) Arzneimittel mit chymaseinhibitoren als wirksames mittel zur behandlung von dermatitis mit zweiphasigen hautreaktionen
DE602004029993D1 (de) Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit
ATE448796T1 (de) Arzneimittel zur behandlung von tumoren und deren metastasen unter verwendung eines bindemoleküls gegen das bone-sialoprotein
ES2105643T3 (es) Uso de la 2-(4-(4-clorofenil)ciclohexil)-3-hidroxi-1,4-naftoquinona para el tratamiento del cancer.
SE0203817D0 (sv) New composition
DK0707477T3 (da) Anvendelse af Efaxoran og derivater deraf til fremstilling af lægemidler beregnet til behandling af neurodegenerative sygdo
ATE147978T1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit